Latest News and Press Releases
Want to stay updated on the latest news?
-
ROSEVILLE, Minn., March 29, 2023 (GLOBE NEWSWIRE) -- Hawkins, Inc. (Nasdaq: HWKN), announced today that it has again been certified as a Great Place to Work. Great Place to Work is an independent...
-
MINNEAPOLIS, March 29, 2023 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access,...
-
RESTON, Va., March 29, 2023 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, announced its financial results for the year ended December 31,...
-
NEW YORK, March 29, 2023 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced that it will release its earnings for the first quarter of 2023...
-
DALLAS, March 29, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, late-stage clinical biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian...
-
March 29, 2023Announcement no. 2 US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not...
-
MIDLAND, Texas, March 29, 2023 (GLOBE NEWSWIRE) -- Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback”), today announced that it plans to release first quarter 2023 financial results on May 1,...
-
MIDLAND, Texas, March 29, 2023 (GLOBE NEWSWIRE) -- Viper Energy Partners LP (NASDAQ: VNOM) (“Viper”), a subsidiary of Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback”), today announced that it...
-
RESEARCH TRIANGLE PARK, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today acknowledged the many contributions of Robert A. Ingram, the company’s chairman...
-
Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
Generated record total revenues of $73.7 million for the full year 2022 Completed enrollment in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea; topline data...